Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Inclusion Criteria: * Patient must be ≥18 years of age * Patient must have histologically or cytologically confirmed solid tumor, including glioma, with documented IDH1 and/or IDH2 gene-mutation. Patients in the dose escalation phase must have disease that has recurred or progressed following standard therapy and/or therapy with an inhibitor of mutant IDH1 and/or IDH2, or that has not responded to this therapy. Patients in the expansion phase may have previously untreated disease * Patient must have evaluable disease by RECIST v1.1 for patients without glioma or by RANO or RANO LGG criteria for patients with glioma * Patients with glioma must have a baseline brain MRI scan * Patient must have archived primary tumor biopsies or surgical specimens, or biopsies of recurrent or metastatic samples * Patient must be amenable to serial peripheral blood sampling, urine sampling, and tumor biopsies during the study * Patient must be able to understand and willing to sign an informed consent * Patient must have ECOG PS of 0 to 2 * Patient must have expected survival of ≥3 months * Patient must have adequate bone marrow function as evidenced by absolute neutrophil count ≥1.5 ×10\^9/L; hemoglobin \>9 g/dL (Patients are allowed to be transfused to this level); platelets ≥75 × 10\^9/L * Patient must have adequate hepatic function as evidenced by: Serum total bilirubin ≤1.5 × upper limit of normal (ULN), unless considered due to Gilbert's disease or disease involvement; Aspartate aminotran…